peptideone
← All peptides

MGF

Status unknown

MGF is classified under igf & growth-factor peptides.

What the research says

Aggregated from the cited literature below. We summarize sources — we don't author claims.

In the provided sources, “MGF” is described in multiple experimental contexts as mechano growth factor (MGF) and/or an MGF E peptide (often focusing on MGF E-domain peptides such as T-MGF-19E or MGF E peptide). Research investigated MGF/MGF E peptides in preclinical models of bone repair (including osteoblast/BMSC responses and rabbit injury/rupture models), and in cell-based settings related to apoptosis/angiogenesis in anterior cruciate ligament (ACL) repair.

Mechanism (as reported)

A mechanistic theme across the provided studies is that MGF or MGF E peptide can influence cell survival and differentiation pathways under hypoxic conditions. Reported pathways/components include HIF-1α regulation and apoptosis signaling (including caspase-related measurements) as well as signaling pathway involvement such as MEK-ERK1/2 and PI3K-Akt. (PMIDs: 30317597, 28927682, 24908137)

Key findings (each cites a source)

  • A study reported that MGF-19E (an MGF E peptide variant) promoted proliferation, differentiation, and mineralization of MC3T3-E1 osteoblast cells, and that a rabbit bone defect model showed improved bone injury healing after candidate MGF E peptide treatment, with T-MGF-19E described as showing particularly significant effects on mineralization in vitro. [PMID 32339623]
  • Research reported that MGF E peptide protected ACL fibroblasts against hypoxia-induced apoptosis, associated with effects on HIF-1α expression and apoptosis-related caspase and protein measurements, and that implicated pathways included MEK-ERK1/2 and PI3K-Akt; the same study reported effects in a rabbit ACL rupture model (including decreased HIF-1α expression, reduced apoptosis, and facilitated cell proliferation) and reported accelerated angiogenesis associated with an SDF-1α/CXCR4 axis and increased VEGF-α expression level. [PMID 30317597]
  • A study reported that MGF E peptide pretreatment improved proliferation and osteogenic differentiation of BMSCs under severe hypoxia (simulated with CoCl2), with reported inhibition of HIF-1α expression/translocation and involvement of MEK-ERK1/2 and PI3K-Akt signaling; the study also reported that short-time treatment with MGF E peptide alone promoted osteogenic differentiation. [PMID 28927682]
  • A study reported that PEGDMA hydrogel microrods loaded with MGF peptide achieved sustained delivery (measured as delivery for about 2 weeks) and showed increased migration of human mesenchymal stem cells; the study also reported reduced apoptosis in neonatal rat ventricular myocytes under hypoxia as assessed by TUNEL and increased Bcl-2 expression, while microrods without MGF were also reported to affect cytoskeleton/adhesion/proliferation of hMSCs. [PMID 24908137]

Independent test grades

No independent third-party test data is available for MGF yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.

Research literature (8)

Consolidated from PubMed — each links to the original record.

FAQ

What is MGF?
MGF is classified under igf & growth-factor peptides. Research goals associated with it include recovery & tissue repair, body composition & muscle.
Is MGF FDA-approved?
The regulatory status of MGF is not established in our sources.
What does the research on MGF say?
peptideone aggregates 8 references from PubMed for MGF. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.
Aggregated from public sources, with attribution. Not medical advice; compounds discussed are not approved for human consumption. Last updated 2026-06-15.